



[Home](#) [Support ISMP](#) [Newsletters](#) [Webinars](#) [Report Errors](#) [Educational](#) [Store](#) [Consulting](#) [FAQ](#) [Tools](#) [About Us](#) [Contact Us](#)





[QuarterWatch Main Page](#)

Resources

- [Drug Index](#)
- [Disclosure & Staff](#)
- [Detailed Methods](#)

QUARTERWATCH TEAM AND FUNDING SOURCES

QuarterWatch is published by the Institute for Safe Medication Practices as a public service. It has no regular income, foundation grant, or other dedicated financial support and is provided to the public and health professions without charge. We seek outside peer reviewers for each issue but their identities are not disclosed. QuarterWatch's essential costs are funded from the general budget of ISMP, a non-profit organization dedicated solely to promoting the safe use of medication. ISMP, in turn, is supported by charitable donations, volunteer efforts, foundation grants, and subscription income from its four other medication safety newsletters, for pharmacists in the acute care and ambulatory care settings, for nurses, and for consumers.

Thomas J. Moore serves as a part-time project director for QuarterWatch. He has developed and maintains the master adverse event database that serves as the primary data source for the publication and conducts the primary analysis for each issue. Mr. Moore receives an honorarium from ISMP for each issue, with the remaining work being on a volunteer basis. He is also a lecturer in the Department of Epidemiology and Biostatistics in The George Washington University Milken Institute of Public Health. Mr. Moore also conducts and publishes other independent studies in the peer-reviewed scientific literature and works as a consultant on drug safety issues, doing business under the name Drug Safety Research. He was a consulting expert to the Attorney General of the State of Texas in a Medicaid fraud lawsuit against Johnson & Johnson regarding the antipsychotic drug Risperdal (risperidone), and was an expert witness for the United States Army and for a civil defendant in connection with criminal cases involving Chantix (varenicline). He also worked as a consulting expert for plaintiffs in the civil litigation regarding Chantix. In 2011 Mr. Moore examined the completeness and accuracy of adverse drug event reports for biological products for Amgen. In 2012 he was a consulting expert for the plaintiffs in the Celexa and Lexapro Marketing and Sales Practices Litigation. In 2014 he was a consulting expert for the plaintiffs in federal whistleblower litigation involving Elidel (pimecrolimus).

Curt D. Furberg, MD, PhD is a Professor Emeritus of Public Health Sciences at Wake Forest University School of Medicine and serves as senior medical adviser to QuarterWatch. He receives no compensation for his work in assessing scientific evidence, defining safety issues, shaping the written report, and communicating with the FDA and others about QuarterWatch findings. He continues to have a research role at Wake Forest and has published more than 400 peer-reviewed scientific articles. An expert on clinical trials of drug treatments, Dr. Furberg is author of a major textbook on that subject, and has worked for the National Institutes of Health and the pharmaceutical industry as an investigator in clinical drug research. He has recently given expert testimony or depositions in cases involving Chantix (varenicline), COX-2 inhibitors, Yaz, Yasmin, **Vytorin**, and Fosamax (alendronate), and has become an expert in the litigation involving Pradaxa (dabigatran). Dr. Furberg is a member of the British Medical Journal Advisory Board.

Donald R. Mattison, MD, MS is a retired captain in the United States Public Health Service who has held senior positions at the National Institutes of Health and in graduate public health education. He is currently chief medical officer and senior vice president of Risk Sciences International in Ottawa, Canada, and associate director of the McLaughlin Centre for Population Health Risk Assessment at the University of Ottawa. He is author of more than 150 peer-reviewed scientific studies and is an elected member of the Institute of Medicine, the Royal Society of Medicine, the New York Academy of Medicine, and the American Association for the Advancement of Science. Risk Sciences International is a consulting company, established in partnership with the University of Ottawa, specializing in the assessment, management, and communication of health and environmental risks. The company has clients in government, industry, and academia, including Health Canada and the FDA.

Michael R. Cohen, RPh, MS, ScD (hon), DPS (hon), FASHP is founder and President of ISMP and guides the overall policies and content of QuarterWatch. He also edits the other ISMP newsletters and is author of the textbook *Medication Errors*. He has served as an advisor and consultant to the FDA, and for his work in medication safety was recognized as a MacArthur Fellow by the John D. and Catherine T. MacArthur Foundation. Dr. Cohen receives a regular salary as president of ISMP and does not engage in outside consulting or legal testimony.

Vytorin is a combination of simvastatin and ezetimibe

**BE A MEDICATION SAFETY LEADER
SUPPORT THE ISMP CHEERS AWARDS**



[Home](#) | [Contact Us](#) | [Employment](#) | [Legal Notices](#) | [Privacy Policy](#) | [Help Support ISMP](#)

[Med-ERRS](#) | [Medication Safety Officers Society](#) | [For consumers](#)
[ISMP Canada](#) | [ISMP Spain](#) | [ISMP Brasil](#) | [International Group](#) | [Pennsylvania Patient Safety Authority](#)

200 Lakeside Drive, Suite 200, Horsham, PA 19044, Phone: (215) 947-7797, Fax: (215) 914-1492
© 2014 Institute for Safe Medication Practices. All rights reserved

